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1. Introduction
Human respiratory syncytial virus (RSV) is a ubiquitous virus of worldwide distribution
and is the leading cause of infant morbidity from respiratory infections. By the age of two
years nearly all children have been infected and can cause severe bronchiolitis and pneumo‐
nia in this age group (Hall et al., 2009). Nearly 100% of children in the USA are infected with
the virus by 2 to 3 years of age, several hundred infants may die directly from the infection,
while the deaths of an additional several thousand may be attributed to RSV-related compli‐
cations (Nair et al, 2010). The World Health Organization estimates that (RSV) is responsible
for 64 million infections worldwide and 160,000 deaths per annum (Openshaw, 2002).
Although mostly young infants are affected, it is increasingly recognized as a significant
cause of disease in the elderly population and can often be fatal for patients with impaired
immune systems (Collins and Malero., 2011). The incubation period of RSV respiratory dis‐
ease is estimated to be three to five days (Black, 2003). The virus can remain viable on hard
surfaces (e.g., countertops) for up to 6hr, on rubber gloves for 90min, and on skin for 20min.
(Hall et al., 1980). This prolonged survival highlights the need (and effectiveness) for hand
washing and contact precautions in limiting the spread of RSV infection (Koetz et al, 2006).
Viral shedding is significantly prolonged in immunocompromised individuals, and can con‐
tinue for several months (Hall et al., 1981; Simoes, 2003).
2. Spectrum of respiratory disease
The spectrum of clinical manifestations ranges from mild upper tract illness, infection in
middle ear which progresses to acute otitis media, croup, to apnoea in premature infants,
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pneumonia and bronchiolitis (Hall et al., 1975). At the beginning of the illness, the virus rep‐
licates in the nasopharynx. Common symptoms of an upper respiratory tract infection in‐
clude a productive cough and mild to moderate nasal congestion with clear rhinorrhea.. A
low-grade fever presents in the early stages of the infection and symptoms may persist for
one to three weeks before complete recovery (Welliver, 2003).
Symptoms of lower respiratory tract disease include tachypnea (ie rapid breathing great‐
er  than  60  to  70  breaths/min),  wheezing,  and/or  rales,  that  usually  appear  up  to  three
days following onset  of  rhinorrhea.  These symptoms are indicative of  the virus spread‐
ing  into  the  bronchi  and  bronchioles.  A  chest  radiograph  exhibits  hyperinflation  with
flattened diaphragms. If the RSV further spreads to the alveoli, an interstitial pneumonia
may  develop,  with  middle  and  upper  lobes  affected.  In  such  patients,  tachypnea  be‐
comes  severe  respiratory  distress,  with  deep  retractions  and  grunting  respirations.  The
risk  for  cardiovascular  failure  secondary  to  hypoxemia,  acidosis,  and  dehydration  in‐
creases  significantly  (Greenough,  2002).  Immunocompromised  and  young  infants,  who
have very narrow bronchioles,  are at  particularly high risk for complete bronchiolar ob‐
struction.  The risk for vomiting also increases,  which is  often related to respiratory dis‐
tress and can increase the likelihood and of gastroesophogeal  reflux.  This may result  in
decreased oral intake with dehydration. Premature babies born at 30–35 weeks of gesta‐
tion, HIV-infected patients, infants with cyanotic congenital heart disease,, and other im‐
munosuppressive  therapy  such  as  bone  marrow  transplant  are  at  increased  risk  for
morbidity and mortality during RSV infection (Resch, 2011).
3. The structure of respiratory syncytial virus
RSV is a member of the subfamily Pneumovirinae in the family Paramyxoviridae, order Mono‐
negavirales. RSV is closely related to several other RNA viruses, including measles, mumps,
and parainfluenza types 1, 2, and 3. Respiratory syncytial virus is a medium-sized
(120-200nm) enveloped virus that contains a lipoprotein coat and a linear minus-sense RNA
genome. The entire genome of RSV is composed of approximately 15,000 nucleotides long
(Dickens et al., 1984).
The genome contains 10 mRNAs, each coding for an individual protein (McIntosh,.1997).
The  structural  proteins  are  divided  into  three  functional  groups,  the  nucleocapsid  (N)
protein, phosphoprotein (P) and viral polymerase (L). These proteins together, have been
demonstrated  to  function  as  the  RSV  replicase.  The  outer  envelope  is  lined  internally
with matrix (M) protein and is spiked externally with fusion (F) and attachment (G) gly‐
coprotein projections, these are responsible for the initiation and propagation of an RSV
infection (Empey et al., 2010). Another protein (M2) is also present in the viral envelope.
The  viral  capsid  is  made  up  of  a  nucleoprotein,  a  phosphoprotein,  and  a  polymerase
protein (C). The F protein is a type 1 transmembrane glycoprotein with a Cleaved N-ter‐
minal signal sequence and a transmembrane anchor near the C terminus. It is cleaved in‐
to  two  subunits,  F1  and  F2  that  are  linked  by  disulfide  bonds,  after  synthesis  and
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modification by the  addition of  N-linked sugars.  The G protein  is  of  particular  interest
because variability in this protein is greater than that in the other proteins both between
and within the major antigenic groups of RSV (Sullender, 2000).
4. Mechanism of infection
RSV does not normally replicate outside of the bronchopulmonary tree and is restricted to
the respiratory mucosa (Othumganpat et al, 2009). The G protein initiates attachment of the
virus to the epithelial cell. The virus fuses with the epithelial cell membrane and enters the
cytoplasm after the F protein is cleaved by proteolytic enzymes of the infected cell. If the
precursor is not cleaved it has no fusion activity, virion penetration will not occur and the
virus particle is unable to initiate infection. Fusion by F1 occurs at the neutral PH of the ex‐
tra cellular environment, allowing release of the viral nucleocapsid directly into the cell.
This enables the virus to bypass internalization through endosomes. After replication the vi‐
rus matures by budding from the cell surface. The new progeny nucleocapsids form in the
cytoplasm and move to the cell surface. The M protein is essential for particle formation,
probably serving to link the viral envelope to the nucleocapsid. During budding, most host
proteins are excluded from the membrane. If appropriate host cell proteases are present,
precursor proteins in the plasma membrane will be activated by cleavage. Activated fusion
protein will then cause fusion of adjacent cell membranes, resulting in formation of large
syncytia (Jawetz et al., 2004). The viral RNA can spread without forming complete viral par‐
ticles. The infection results in the destruction of the epithelial cells of the upper respiratory
tract. Exposure to RSV triggers humoral immune responses. Primary RSV infection results
in only a weak antibody response with IgM, IgG, and IgA produced. This response is not
sufficient to completely destroy the virus or to prevent upper respiratory tract replication of
the virus, thus an upper respiratory tract illness develops (Smith et al., 2009).
Although, RSV mostly infects the nasal epithelial cells. However, development of extrapul‐
monary disease has been observed in certain T and B cell immunodeficiency states. The as‐
sociation of RSV with asthma and reversible reactive airway disease in early childhood has
attracted significant attention (Mohapatra et al., 2008). Recurrent wheezing for up to 5 to 7
years of age and established airway disease has been observed in a significant number of
children with a strong family history of allergy, after primary infection or reinfection with
RSV (LeManske, 2004). Immune response to primary infection is relatively small but on rein‐
fection, a significant booster effect with sustained immunologic reactivity is observed in se‐
rum and respiratory mucosa. Both CD4- and CD8-specific as well as Th1- and Th2-cell
specific immune responses have been observed during human infection. In addition, proin‐
flammatory as well as immunoregulatory cytokines and chemokines are induced in the res‐
piratory tract after natural and induced (in vitro) infection. In vulnerable patients, the RSV
infection will spread into the lower respiratory tract (Becker et al., 2006). In premature in‐
fants and immunocompromised hosts, the infection quickly progresses to the LRT. As the
virus is destroyed within the lung by T cells, immunopathological responses cause further
lung injury. Infected cells release proinflammatory cytokines and chemokines, including in‐
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terlukins (IL-1, IL-6, and IL-8) and tumor necrosis factor-alpha (TNF-α). These actions result
in activation of inflammatory cells, including macrophages, eosinophils, neutrophils, and T
lymphocytes, into the airway lining and surrounding tissues.
5. Molecular epidemiology of RSV
Variability between RSV strains contributes to the ability of the virus to infect people repeat‐
edly and cause annual outbreaks. Consistent shifts in RSV group dominance have been re‐
ported worldwide in which RSV group A viruses are more frequently detected. A new BA
genotype was identified in Buenos Aires in 1999 that is characterized by a 60-nucleotide du‐
plication starting after residue 791 of the G protein. Subsequently, strains with this duplica‐
tion have been found in clinical specimens from distantly related places in the world,
including Kenya in East
Figure 1. Mechanism of RSV Virus Entry and Replication in Respiratory Virus Infection
Africa. This BA genotype was first discovered in South Africa during the investigation of
a nosocomial outbreak in Pretoria in 2006. (Niekerk and Venter, 2011). In Germany, RSV
group A was  dominant  in  seven  out  of  nine  epidemic  seasons  predominating  between
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1999 to 2007 seasons. During the same periods, mainly RSV group A dominated in sev‐
eral other countries.
The subgroup prevalence and genotype distribution patterns of RSV strains were investigat‐
ed in a community in Belgium during 10 successive epidemic seasons (1996 to 2006). A regu‐
lar 3-year cyclic pattern of subgroup dominance was observed, consisting of two
predominant RSV-A seasons, followed by a single RSV-B-dominant year. RSV infections
with both subgroups were more prevalent among children younger than 6 months and had
a peak incidence in December. The most frequently detected genotypes were GA5 and
GB13, the latter including strains with the 60-nucleotide duplication in the G gene (Zlateva
et al, 2007). A study in India reported on RSV group A dominance for three consecutive epi‐
demic seasons. RSV group B predominated for a single season in the countries investigated
and at the same or similar time as observed in Germany. Thus, it can be concluded that RSV
group A predominated within similar seasons, implicating that most RSV infections were
caused by RSV group A worldwide at the same time.
The results of the first study to investigate the circulation and genetic diversity of RSV in
Cambodia among different age ranges of population over 5 consecutive years (Arnott, et al.,
2011). Circulation of RSV was seasonal, coinciding with the rainy season between July and
November. The majority of RSV group B strains belonged to the BA genotype, with the ex‐
ception of 10 strains classified as belonging to a novel RSV group B genotype,
In an Iranian study during the season 2009, samples were obtained from several provinces:
Tehran, Hamadan, Isfahan, Kordestan, Zanjan, Lorestan and West Azarbayjan, and were
tested for G protein gene of RSV by RT-PCR (Faghihloo et al., 2011). Of the respiratory sam‐
ples tested, 22% were positive for RSV, of which 67% belonged to subgroup A and 33% to
subgroup B. Phylogenetic analysis revealed that subgroup A strains fell in two genotypes
GA1 and GA2, whereas subgroup B strains clustered in genotype BA. This study revealed
that multiple genotypes of RSV cocirculate in Iran. Subgroup A strains are more prevalent
than subgroup B strains, with genotype GA1 predominant.
There has been a distinct lack of data from the Middle East in terms of molecular typing of
RSV. For example, In Saudi Arabia, only few reports have described the prevalence of RSV
infection in sporadic districts of the kingdom including Riyadh, Al-Quassim and Abha (Jam‐
joom et al., 1993; Bakir et al., 1998; Al-Shehri et al., 2006; Meqdam and Subiah, 2006, Akhter
and Johani., 2011). These reports covered short periods of time extending from 1991-1996,
2003-2004 and 2004-2010. Both virus subtypes in RSV infection of Saudi Arabia children are
found to occur with a greater dominance of type A viruses in a three year cyclical pattern.
However, a greater interest in RSV is needed for proper virus characterization. Molecular
typing studies are required to elucidate the nature of RSV spread in these populations.
Similar viruses were first isolated around the same time in Europe, USA, The Gambia, Ma‐
laysia, Uruguay and Australia (Cane and Pringle, 1995). Further studies in North America
(Peret et al., 2000), Europe (Lukic-Grlic et al., 1999), and Africa (Cane et al., 1999, Venter et
al., 2002) have shown that similar strains of RSV appear simultaneously in indistinct geo‐
graphic locations in these areas. It is clear that infections with very similar viruses may be
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occurring world-wide during the same season. Overall there appears to be very little geo‐
graphic clustering of RSV strains and where this has been reported it may often be due to
inadequate sampling or delayed reporting of strain variability, particularly from less devel‐
oped parts of the world. As the virus is constantly accumulating genetic and antigenic
change, this implies that when a new strain arises it is able to spread very rapidly around
the world.
6. Vaccines
There have been exhaustive attempts to identify pharmacological therapies to improve the
clinical course and outcomes of this disease. However, presently, there is no licensed vac‐
cine against RSV. High-risk infants can be substantially protected by monthly intramuscular
injections of a commercially available RSV-neutralizing antibody (palivizumab) adminis‐
tered during the RSV epidemic season (American Academy of Pediatrics, 2003). RSV is the
focus of antiviral- and vaccine-development programmes because of the morbidity and mor‐
tality associated with bronchiolitis early in life. However, these goals are now being aided
by an understanding of the virus genome architecture and the mechanisms by which it is
expressed and replicated (Meisner and Long, 2003).
The reasons why an RSV vaccine is not yet available emanate from numerous problems with
its development. First, is the possibility that vaccination will potentiate naturally occurring
RSV disease, as observed with the formalin-inactivated vaccine (Domachowske and Rosen‐
berg, 1996). Second, young infants exhibit relative immunologic immaturity or because of
suppression of their immune response due to circulating maternally derived anti-RSV anti‐
bodies (Falsey and Walsh, 1996). Another important consideration is the need to provide
protection against multiple antigenic strains of RSV in the two major groups, A and B. A
number of strategies have been implemented recently to generate safe and effective subunit,
inactivated, and live attenuated virus vaccines (Falsey and Walsh, 1997).
7. Inactivated and subunit respiratory syncytial virus vaccines
The first attempt at an RSV vaccine in the 1960s employed formalin-inactivated RSV parti‐
cles (FIRSV). This vaccine failed to induce a protective immune response and led to en‐
hanced disease upon natural infection with wild type (wt) RSV. As a result, 80% of the
children vaccinated needed to be hospitalized following wt RSV infection, and two children
died (Kim et al., 1969). Consequently, there was great apprehension to study any nonrepli‐
cating RSV vaccine in seronegative infants and children. Enhanced disease has never been
observed with live attenuated vaccines and it is not seen in seropositive subjects, neither
with inactivated nor with subunit RSV vaccines (Collins et al., 2001).
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8. Sub unit vaccines
A large number of subunit vaccines have been studied in preclinical trials, and some have
progressed into clinical trials. Most of these candidate vaccines consist of either or both of
the RSV surface glycoproteins that mediate membrane fusion (F) and virus attachment (G).
These vaccines were administered in various ways, such as using alum phosphate or alum
hydroxide. Others were evaluated conjugated to bacterial toxins, as ISCOMs (immunosti‐
mulating complex), or with adjuvants such as CpGs (CpG-DNA), monophosphoryl lipid A,
saponines, or oil-in-water emulsions (Piedra, 2003; Kneber and Kimpen, 2004). The use of in‐
activated and subunit vaccines seems safe in RSV seropositive individuals, however, two ex‐
ceptions have been noted in seronegative infants: FI-RSV and subunit vaccines induced high
RSV-binding antibody titers with low neutralizing activity and the enhanced disease seen
with FI-RSV can be replicated in rodent models using subunit vaccines.(Openshaw et al.,
2001; Johnson et al., 2004)
One of the more recent trials evaluated PFP-3 (purified F protein with aluminum phosphate)
in seropositive children 1 to 12 years of age with cystic fibrosis. In this trial, PFP-3 was
found to be safe and immunogenic but not protective. Similarly, in a trial of PFP-2 in healthy
pregnant women and their offspring, PFP-2 was found to be safe but there was no signifi‐
cant increase in RSV neutralizing IgG titers following vaccination in the third trimester so
that a protective effect in the offspring could not be expected (Munoz et al., 2003). A differ‐
ent subunit vaccine was tested consisting of copurified F, G, and M proteins from RSV sub‐
group A (sanofi-aventis, Bridgewater, NJ) in a phase 1 trial in healthy adult volunteers. Of
those vaccinated, 80% developed a greater than fourfold increase in neutralizing antibody
titers to RSV A and RSV B. However, these titers did not persist so that annual vaccination
would be necessary to maintain potentially protective antibody titers with this candidate
vaccine (Wright et al., 2000). BBG2Na (Pierre Fabre, Castres, France), a promising vaccine
candidate that was developed by fusing the conserved central domain of the RSV G protein
to the albumin-binding region of streptococcal protein G, was found to be safe and immuno‐
genic in phase 1 and phase 2 studies. But in the phase 3 trial purpura / type III hypersensi‐
tivity resulted as an unexpected side-effect in a small number of vaccine recipients and so
halted further development (Kneyber and Kimpen., 2003).
9. Live attenuated respiratory syncytial virus vaccines
Several live attenuated RSV vaccines have been identified by passage of RSV under different
conditions such as lower temperatures, temperature- sensitive (ts), chemical mutagenesis
and non-ts attenuating mutations. Several candidate vaccines went into clinical trials, but it
was not possible to find an appropriate balance between immunogenicity and attenuation,
particularly in young infants.
The development of a method to generate infectious virus from a cDNA copy of the nega‐
tive-sense single-stranded virus genome initiated the era of rational RSV vaccine design. It
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allowed the use of site-directed mutagenesis to introduce desired mutations into the RSV ge‐
nome and to evaluate the contribution of each mutation to the attenuation phenotype by in‐
troducing individual mutations or sets of mutations into the RSV genome. Reverse genetics
has also been used to generate attenuated deletion mutants that are useful as live attenuated
RSV vaccines. Deletion of the genes for the interferon antagonists NS1 or xlink, the small hy‐
drophobic gene SH, or the M2–2 regulator of transcription and replication produced viable
viruses that displayed restricted replication in nonhuman primates. Candidate vaccines
bearing these deletions with or without additional attenuating point mutations were identi‐
fied as suitable for clinical development (Collins and Murphy, 2005).
A promising candidate vaccine is an RSV subgroup A mutant designated
cp248/404/1030ΔSH. This mutated virus has 11 mutations identified in the biologically de‐
rived cpts248/ 404RSV, a further mutation in the large polymerase protein L (the 1030 muta‐
tion), and a deletion of the SH protein. It was was evaluated in a phase 1 trial in 1- to 2-
month-old infants, replication was highly restricted in seronegative infants and the vaccine
was well tolerated (Karron et al., 2005). Although neither systemic nor mucosal antibody re‐
sponses were repeatedly observed in the youngest vaccinated infants, but complete restric‐
tion of a second dose of vaccine given 4 weeks after the first dose indicated that protective
immunity could be induced.
10. Future strategies
One of the most promising current strategies for protection against respiratory tract infec‐
tion is intranasal treatment with vectors capable of generating RNAs that block viral replica‐
tion. RNA interference (RNAi) is a natural defense of the innate immune system against
viruses (Dallas and Vlassov, 2006). Following viral replication, double-stranded viral RNA
is recognized by the host RNAi system which cuts it into short oligoribonucleotides, 20–30
bases long. These short sequences activate the cell’s RNA cleavage machinery (the RNA in‐
terference silencing complex, or RISC) to destroy the viral RNA. By introducing siRNAs
complementary to specific viral mRNAs, double-stranded activating RNA can be generated
that activates the RISC cleavage system and destroys the viral message. This approach using
antiviral siRNA has been reviewed by Manjunath et al, 2009. The use of siRNA as an antivi‐
ral agent involves a relatively straightforward attack on one or more key viral genes and
should be effective against many human pathogens. The use of non-integrating plasmid vec‐
tors removes the risk of mutagenesis caused by some viral vectors.
11. Summary
The burden of acute respiratory infections (ARIs) caused by viral pathogens is impressive
and leaves no doubt that effective and affordable vaccines are urgently needed. The impact
of respiratory viral infection is greatest in the very young, the elderly, and people with an
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impaired immune system or other chronic conditions. LRIs are a common cause of hospital
admission and excess mortality. RSV infection is the most frequent etiology of a child’s first
LRI. Presently, passive protection against RSV is achieved successfully through monthly in‐
tramuscular injection of the humanized monoclonal anti-RSV antibody palivizumab How‐
ever, immunoglobulin products are expensive to administer
Attempts to develop a vaccine against RSV have been unsuccessful to date. A formalin-inac‐
tivated RSV vaccine was developed in the 1960s. Although initial serological responses to
this vaccine appeared promising, children who received this vaccine developed more severe
disease, with a number of deaths, when exposed to natural RSV infection. The development
of a successful RSV vaccine must address this issue and achieve protection of very young
children if it is to have an impact on severe RSV disease. Recent progress in this area has
included development of stable, live-attenuated RSV vaccines that can be administered as
nasal spray. Despite progress in this area, a vaccine that is ready for use in clinical practice is
still many years away.
Another approach is the development of an RSV vaccine that involves use of cloned RSV
surface proteins as potential subunit vaccines. RSV fusion (F) and glycoprotein (G) can in‐
duce neutralizing and protective antibodies and are the components in development. Phase
1 trials of Fusion (F) protein nanoparticle RSV vaccine candidates have shown that they are
generally well-tolerated, highly immunogenic and produce functional antibodies that neu‐
tralize RSV. These are being evaluated for potential immunization of young children and al‐
so for administration to pregnant women during the last trimester to boost anti-RSV
antibody levels transferred to the infant (Schmidt, 2007).
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